In this informative panel discussion, Fintan Walton talks with 3 members of PharmaVentures’ deal advisory team about Royalty Rates, particularly the valuation of deals in the pharmaceutical and biotech industry, and the challenge to find information about Royalty Rates not generally available in the public domain.
Dr Tibor Papp, Head of Advisory, outlines how the consultancy team would advise clients to enable them to arrive at the best Royalty Rates for their deals in the intensive deal-making environment.
Nigel Borshell, Senior Consultant, and the editor of the soon-to-be-published PharmaDeals® Report,
The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector, talks about the methods used for calculating Royalty Rates; use of NPV calculations, market benchmarks, the application of “Real Options” and the 25% rule of thumb.
Steven Renwick, Consultant, who was involved in the design and execution of the recent LES Royalty Rates Survey, talks about the research findings, such as the different valuation methods used by pharmaceutical companies, biotechs, universities and research institutes.
Watch this interview now to find out more about Royalty Rates and how they can be used to increase flexibility around the deal negotiation process.
For further information on The Comprehensive Guide to Royalty Rates in Pharmaceutical and Biotech Deals. 2009 Edition, please
visit our website or
contact The PharmaDeals Team on +44 (0) 1865 784 177.
View the
table of contents
Order now: The report is currently available at a 10% pre-publication price.
Buy online
Download an
order form
PharmaDeals® is the publishing imprint of PharmaVentures Ltd.